Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 1999

View Archived Issues

Study results presented for ViroPharma's antiviral agent pleconaril

Angiotech presents positive results from phase I/II MS study

Exisulind leads to lower PSA levels according to interim phase II/III data

Licensing opportunity from Stanford University: treatment of autoimmune disorders

Ligand confirms that ECOG has initiated multicenter phase II study of Ontak for NHL

Gliatech files IDE for ADCON-A antiadhesion barrier

PathoGenesis launches TOBI in second market

Company Profile: Onconova Therapeutics

Inspire presents positive results for dry eye disease therapeutic

Antibody-gold cluster conjugates with broad potential application available for licensing

Duramed's conjugated estrogens now available in U.S.

Novo Nordisk presents new insulin delivery system

New selective 5-HT1B receptor antagonists disclosed by Astra (AstraZeneca)

Magainin: Annual Report 1998

Triangle, Glaxo Wellcome and Emory University resolve emtricitabine dispute

Carbapenems from Merck particularly active against methicillin-resistant Gram-positive pathogens

P&G presents new antimicrobial agents with broad spectrum, including resistant bacteria

CETP inhibitors in the Bayer pipeline

Thrombin inhibitors developed by Merck scientists

Second COX-2 inhibitor reaches the market

Cartilage-derived angiogenesis inhibitor is potentially useful in treating proliferative retinopathy

New benzazepine compound selectively inhibits vitronectin receptors

Spanish team develops microsphere delivery system for improved intravitreal use of corticosteroids

Solvay expands cardiovascular product portfolio

European Union approval obtained for Schering-Plough's combination HCV therapy

CoCensys sells holdings in Cytovia

Sunrise Technologies' hyperopia treatment system scheduled for FDA advisory panel review

Enbrel warning related to infections issued by FDA and Immunex

Oral creatine is neuroprotective in transgenic mouse model of ALS

Brain COX-2 expression and arteriolar vasodilatation in response to inflammatory stimuli

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Medline raises $6.3B in fourth med-tech IPO of December
BioWorld MedTech
Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
Vitesse finesse pays off: DBV wins in peanut allergy phase III
BioWorld
DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....
Acryl raises $28M IPO, aiming to bridge medical divide with AI
BioWorld MedTech
Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...